What Avidity Partners Management LP reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1791827 · Filed Nov 16, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 1.3M |
| −3.6% |
| $95.6M |
| 19.6% |
ORKAOruka Therapeutics, Inc. | 785.4K | +3.3% | $65.4M | 13.4% |
| 850K | New | $60.3M | 12.3% |
JBIOJade Biosciences, Inc. | 2M | +17.6% | $28.1M | 5.8% |
ELVNEnliven Therapeutics, Inc. | 550K | ±0% | $25.2M | 5.2% |
CATXPerspective Therapeutics, Inc. | 6.1M | −3.7% | $16.7M | 3.4% |
AKTSAktis Oncology, Inc. | 484.2K | ±0% | $9.4M | 1.9% |
IMUXImmunic, Inc. | 669.9K | ±0% | $6.2M | 1.3% |
MOBIMobia Medical, Inc. | 324.7K | −59.3% | $3.1M | 0.6% |
PVLAPalvella Therapeutics, Inc. | 20K | −71.4% | $2.8M | 0.6% |
NVCTNuvectis Pharma, Inc. | 100.4K | −49.8% | $2.1M | 0.4% |
MSLESatellos Bioscience Inc. | 164K | −57.7% | $1.4M | 0.3% |
CNTXContext Therapeutics Inc. | 4.1M | −18.8% | $1.2M | 0.2% |
KPTIKaryopharm Therapeutics Inc. | 884.9K | −4.3% | $1.1M | 0.2% |
SENSSenseonics Holdings, Inc. | 100K | −93.8% | $1M | 0.2% |
SCYXScynexis Inc | 153.6K | −41.0% | $758.8K | 0.2% |
AVLNAvalyn Pharma Inc. | 20K | −66.7% | $569.8K | 0.1% |